Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
137M
-
Number of holders
-
196
-
Total 13F shares, excl. options
-
87.6M
-
Shares change
-
-401K
-
Total reported value, excl. options
-
$656M
-
Value change
-
-$4.69M
-
Put/Call ratio
-
9.41
-
Number of buys
-
95
-
Number of sells
-
-105
-
Price
-
$7.49
Significant Holders of Vir Biotechnology, Inc. - Common Stock (VIR) as of Q3 2024
244 filings reported holding VIR - Vir Biotechnology, Inc. - Common Stock as of Q3 2024.
Vir Biotechnology, Inc. - Common Stock (VIR) has 196 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 87.6M shares
of 137M outstanding shares and own 63.81% of the company stock.
Largest 10 shareholders include SB INVESTMENT ADVISERS (UK) LTD (16.7M shares), BlackRock, Inc. (16.4M shares), VANGUARD GROUP INC (13.1M shares), STATE STREET CORP (5.63M shares), ORBIMED ADVISORS LLC (3.57M shares), BAILLIE GIFFORD & CO (2.38M shares), GEODE CAPITAL MANAGEMENT, LLC (2.19M shares), Bill & Melinda Gates Foundation (1.56M shares), MORGAN STANLEY (1.24M shares), and DIMENSIONAL FUND ADVISORS LP (1.21M shares).
This table shows the top 196 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.